Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 27;5(8):2075-2078.
doi: 10.1182/bloodadvances.2020003643.

13q12.2 deletions and FLT3 overexpression in acute leukemias

Caroline Pires Poubel  1   2 , Mariana Boroni  2 , Mariana Emerenciano  1
Affiliations
Comment

13q12.2 deletions and FLT3 overexpression in acute leukemias

Caroline Pires Poubel et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Study overview. (A) TARGET data used for copy number variants assessment in the 13q12.2 region in either T-ALL or AML patients. (B) Schematic figure of the region where FLT3 (light green rectangle) and PAN3 (light blue rectangle) genes are located. (Upper) Wild-type scenario. (Middle) Largest 13p12.2 deletion found by Yang et al. (Lower) Location of 13q12.2 deletion found in the AML patient (highlighted rectangle). DS1 (FLT3 promoter, chr13:28 674,500-28 675,000; dark green rectangle), DS2 (chr13:28 710,000-28 715,000; dark blue rectangle) and DS3 (PAN3 intron 8; chr13:28 843,000-28 843,500; red rectangle). (C) Dispersion of FLT3 expression among AML patients demonstrated by boxplot. The dot plot shows the FLT3 expression of each AML patient (green circle), highlighting the diagnostic (blue square) and relapse samples (red triangle) from the female patient who presented a 13q12.2 deletion. These expression data were obtained according to the availability of RNA-sequencing data from patients assessed for copy-number abnormality (n = 203).
See this image and copyright information in PMC

Comment on

References

    1. Yang M, Safavi S, Woodward EL, et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood. 2020;136(8):946-956. - PMC - PubMed
    1. Poubel CP, Mansur MB, Boroni M, Emerenciano M. FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms. Biochim Biophys Acta Rev Cancer. 2019;1872(1):80-88. - PubMed
    1. Spencer DH. Deletions in BCP-ALL result in a TAD more FLT3. Blood. 2020;136(8):919-920. - PMC - PubMed
    1. Lin M, Wei L-J, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004;20(8):1233-1240. - PubMed
    1. Pounds S, Cheng C, Mullighan C, Raimondi SC, Shurtleff S, Downing JR. Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics. 2009;25(3):315-321. - PMC - PubMed